Pasithea Therapeutics Announces Comprehensive Settlement Agreement with the Camac GroupGlobeNewsWire • 12/12/22
Investor Group Recommends Stockholders Vote the WHITE Proxy Card for Boardroom Change at Pasithea TherapeuticsBusiness Wire • 12/07/22
Pasithea Therapeutics to Present at Annual Meeting of the Antibody Society ConferenceGlobeNewsWire • 12/06/22
Pasithea Therapeutics Postpones Special Meeting until December 9, 2022 at 9:00 AM Eastern TimeGlobeNewsWire • 11/29/22
Pasithea Therapeutics to Present Tolerizing Vaccine Program Results at Immunotherapy 2022 International Course and SymposiumGlobeNewsWire • 10/17/22
Investor Group Comments on Pasithea Therapeutics' Seemingly Defensive and Ill-Timed Acquisition of AlloMek TherapeuticsBusiness Wire • 10/13/22
Pasithea Therapeutics Further Strengthens its Scientific Advisory Board with the Appointment of Dr. Merit CudkowiczGlobeNewsWire • 09/15/22
Pasithea Therapeutics to Present at the H.C. Wainwright 24th Annual Global Investment ConferenceGlobeNewsWire • 09/09/22
Investor Group Successful in Request to Call Special Meeting of Stockholders of Pasithea TherapeuticsBusiness Wire • 09/06/22
Investor Group Urges Stockholders of Pasithea Therapeutics to Vote to Call Special MeetingBusiness Wire • 08/24/22
Pasithea Therapeutics to Present Results of Tolerizing Vaccine Program at Prestigious International Immunotherapy ConferenceGlobeNewsWire • 08/18/22
Investor Group Urges Stockholders of Pasithea Therapeutics Corp. to Call Special MeetingBusiness Wire • 08/05/22
Pasithea Therapeutics Urges Stockholders to Reject Activist Camac Group's Unjustified CampaignGlobeNewsWire • 08/02/22
Investor Group Comments on Pasithea Therapeutics' Seemingly Defensive and Dilutive Related-Party Acquisition of Alpha-5Business Wire • 06/23/22
Pasithea Therapeutics to Participate in the H.C. Wainwright 1st Annual Mental Health Conference: Neuropsychiatry, Psychedelics and BeyondGlobeNewsWire • 06/23/22
Pasithea Therapeutics Announces Financial and Business Results for the Fourth Quarter and Full Year 2021 and Business Update for 2022GlobeNewsWire • 03/30/22
Pasithea Therapeutics Strengthens its Scientific Advisory Board with the Appointment of Preeminent Scientist Dr. Daniel WeinbergerGlobeNewsWire • 02/09/22